Irinotecan (CPT-11) is currently used in cancer chemotherapy given its ability to inhibit topoisomerase I (Jaxel et al, 1989; Bissery et al, 1996; Zamboni et al, 1998). On the basis of large ...

Phase II Trial of Alfimeprase, a Novel-Acting Fibrin Degradation Agent, for Occluded Central Venous Access Devices UGT1A1*28 polymorphism has been associated with decreased glucuronidation of SN38, ...

A prospective trial of gastrointestinal cancer patients showed the feasibility of preemptive genetic testing for DPYD/UGT1A1 variants associated with increased chemotherapy toxicity. Genotype-guided ...

Aug. 26, 2005 — The U.S. Food and Drug Administration (FDA) has approved a pharmacogenetic test to identify patients that may be at increased risk of adverse reactions to the chemotherapy drug ...

Please provide your email address to receive an email when new articles are posted on . The FDA cleared a new test for patients with colorectal cancer who are being considered for, or are currently ...

C4x Discovery Holdings plc has announced further progress in its MALT1 inhibitor program for cancer. Building on anti-cancer activity in a preclinical xenograft study, the company completed a ...

For some patients with gastrointestinal (GI) cancers like colorectal and pancreatic cancer, chemotherapy can cause severe, sometimes life-threatening side effects in those who carry certain genetic ...

Genetic testing of gastrointestinal cancer patients prior to starting chemotherapy proved feasible in a prospective study and showed a signal for a reduced risk of serious side effects. Compared with ...